| Literature DB >> 31068031 |
Takeshi Hagino1, Nelson Hirokazu Tsuno2, Fumihiro Azuma2, Hideo Ohtani3, Reina Matsui3, Chie Someya1, Yutaka Kato1, Satoko Osanai1, Hiroko Hidai1, Hisashi Tsutsumi3, Hideki Akiyama1, Sayuri Motomura1, Tetsunori Tasaki4.
Abstract
The efficacy of 30 platelet concentrate (PC) products transfused to a patient with myelodysplastic syndrome (MDS) was evaluated by calculating the 1-hour post-transfusion corrected count increment (1h-CCI). Of the 30 transfusions, all HLA-A/B-matched, the cross-match (CM) test was negative in 23 (CM(-)-PC) and weakly positive (CM(+)-PC) in 2, and the CM test was not conducted in 5 (non-CM-PC). The effective rate was higher with CM(-)-PC compared to non-CM-PC (82.6% vs 60%), but statistical significance was not achieved, which suggested that the CM test of PC may still be a not satisfactorily effective predictor of PC refractoriness. Studies are ongoing in Japan to confirm on the importance of CM test of PC.Entities:
Keywords: ABH-compatible platelet units; Anti-HLA antibody; corrected count increment; crossmatch-positive platelet units; platelet transfusion refractoriness
Mesh：
Substances：
Year: 2019 PMID： 31068031 DOI： 10.1080/09537104.2019.1609664
Source DB: PubMed Journal: Platelets ISSN： 0953-7104 Impact factor: 3.862